1 / 28

Diagnosis-specific morbidity statistics’ data PROBLEMATIC ASPECTS

Diagnosis-specific morbidity statistics’ data PROBLEMATIC ASPECTS. Based on experiences from work executed within an action „Pilot projects on morbidity statistics” According to the methodology specified in the guidebook

thor
Download Presentation

Diagnosis-specific morbidity statistics’ data PROBLEMATIC ASPECTS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Diagnosis-specific morbidity statistics’ dataPROBLEMATIC ASPECTS Based on experiences from work executed within an action „Pilot projects on morbidity statistics” According to the methodology specified in the guidebook „Principles and guidelines for diagnosis-specific morbidity statistics” Agnieszka Broś Piotr Woch

  2. Focal points • General information on the diagnosis-specific morbidity statistics’ project in Poland • duration, aims, cooperation • National data sources – enumeration, assessment, • Methodology for producing best national estimates • Examples & problematic aspects • Future steps

  3. General information on the action • Duration: 15 November 2009 - 14 May 2011 • The reference year: 2006 • Aims: • Inventory and description of all potential national sources for diagnosis- specific morbiditydatawhich can be used to provide information about diseases listed in the Diagnosis-specific morbidity – European shortlist, SHORTLIST agreed by Eurostat: 60 diseases divided into 20 groups + 1 group covering „external causes of mortality and morbidity” (accidents, assault, poisoning, complications of medical procedures, etc.). 2. Elaboration of the methodology for producing best national estimates 3. Pilot data collectionand testing of the proposed methodology, taking into account the results of former Eurostat projects. 4. Preparation of the final report on the action.

  4. Cooperation – a key issue • Centre for Health Statistics in the Statistical Office in Krakow – leading role in the project • Series of working meetings and consultationswith external experts (from National Institute of Public Health, Oncology Centre, National Health Fund, Institute of Psychiatry and Neurology, Centre for Health Information Systems) …on all steps of the project • discussion of templates for data sources • description and assessment of data sources • analysis of available figures for required measures (incidence, prevalence) Problematic issues discussed with EUROSTAT

  5. Templates in the project • Inventory of national data sources for diagnosis-specific morbidity statistics – template for general overview of the potential data sources • Broad description and evaluation of the data sources inventoried • Relationships between the measures(items on Shortlist) and data sources (potential and finally kept)

  6. DATASOURCES most important & commonly used

  7. Inventory of data sources for diagnosis-specific morbidity statistics (I) First step - identification of all potential data sources • Register of tuberculosis • Notifications of sexually transmitted diseases • Notifications and registration of HIV/AIDS • Notifications of infectious diseases, infections and poisoning • Reports of influenza cases and suspicions of the influenza • National Cancer Register • General in-patientmorbidity study • General out-patientmorbidity study • Psychiatric morbidity study (out-patient & in-patient)

  8. Inventory of data sources (II) First step - identification of all potential data sources • Database of provided healthcare benefits in the framework of the in-patient and out-patient specialist care – NHF (National Health Fund) • Population Health Status Survey in Poland (2004) • Statistical survey of mortality • Police’ databases (on road traffic accidents, attempted suicides, crimes) • Central Register of Occupational Diseases • Databases on disabled people (The Social Insurance Institution & The Agricultural Insurance Fund)

  9. Inventory of national data sources for diagnosis-specific morbidity data (I)DIVISION & ASSESSMENT Assessmentcriteria: relevance, accuracy, timeliness & punctuality, accessibility & clarity comparability (geographical and over time), coherence Assessmentscale: 1 - poor, 5 - very good

  10. Inventory of national data sources (II)further division based on previous assessment Highest rated (mark: 4) – used during project • Main advantages: • confirmation of each case through medical diagnosis • continuity of data supply • whole population covered

  11. Inventory of national data sources (III)further division based on previous assessment Lowest rated (mark: 1-2) - rejected • Main disadvantages: • Lack of cases’ confirmation through medical diagnosis (police’s data) • Reference to population groups, • not to general population • (databases on disabled people, • Register on Occupational Diseases)

  12. Examples & problematic aspects Examples & problematic aspects

  13. Methodology for producing best national estimates Possible ways to approach the production of best estimates (proposed by Eurostat) and their usage during the realization of project: • a one to one relation- with a direct connection between the source and the required measure (for a position of the shortlist of diseases), • the most frequent one • combination of data from various sources • only for several diseases • adjustment of data source in order to find the "perfect figure” • period prevalence on the basis of „Data on out-patient and in-patient morbidity – NHF” • incidence per episode on the basis of „General out-patient morbidity study” All calculated figures inserted in a table for data submission for Eurostat.

  14. Tuberculosis [A15-A18, B90] • Data requirements: incidence by episode, period prevalence • Potential data sources: • Register of tuberculosis, • General hospital morbidity study • General out-patient morbidity study • Database of provided health care benefits in the framework of the in-patient and out-patient specialist care – NHF • Incidence by episode – calculated on the basis of TB cases reported to the Register of tuberculosis • Period prevalence –calculated on the basis of data from National Health Fund

  15. Tuberculosis – a one to one relationship & adjustment Incidence by episode Period prevalence NHF database APPLIED Register of tuberculosis APPLIED All patients treated in hospitals and by specialists All TB cases subjected to the obligatory reporting No information on GP’s patients General hospital morbidity study • Under-registration: • changeability in annual incidence occurred – lack of stability in the scope of detecting and registration, • insufficient knowledge about diagnostic procedures among physicians detected TB among children • Unsatisfactory proportion of cases confirmed by bacteriological tests REJECTED General outpatient morbidity study Hospital study: only in-patients Out-patient study: no data on out-patients cured in specialist care

  16. All malignant neoplasms (cancer) [C00-C97] • Data requirements: incidence by person, period prevalence (5 years) • Potential data sources: • National Cancer Register (NCR) • General hospital morbidity study • Database of provided health care benefits in the framework of the hospital and out-patient specialist care – NHF NCR as a basis for calculation: • Cancer incidence - diagnosis of disease with histological or cytological symptoms or proved by imaging examination or clinic imaging. There can be a few primary cancer sites for a single person. • 5-year prevalence – the number of people living with cancer disease, who have been diagnosed within the last 5 years. Total prevalence should be calculated on the basis of cancer registry data. The NCR does not possesses a long enough horizonof data(20-30 years) to determine the total prevalence, thus 5-year prevalence is applied.

  17. All malignant neoplasm – a one to one relationship Incidence by episode Period prevalence National Cancer Registry National Cancer Registry APPLIED APPLIED 5-year prevalence was estimated by NCR on the basis of incidence data and the 5-year survival rates calculated for the Polish population for patients diagnosed in2000-2002 • Obligatory reporting: • doctors → 16 regional registries (verification, completion) → NCR (next control and medical verification; publishing annual report • Estimated coverage of the NCR exceeds 85%: • before estimation: M – 63,9; W - 60,9 (in thous.) • after estimation: M – 75,2; W - 72,0 (in thous.) • Non-uniform under-registration across the country (high intervoivodship differences) • Registration completeness depends on the cancer site (location) and age group considered General hospital morbidity study REJECTED Hospital study: only in-patients NHF database REJECTED No information on GP’s patients

  18. Acute myocardial infarction (AMI) [I21, I22] • Data requirements: incidence by person, period prevalence • Potential data sources: • General hospital morbidity study • Database of provided health care benefits in the framework of the hospital and out-patient specialist care – NHF • Acute myocardial infarction can be diagnosed based on clinical characteristics, electrocardiographic (ECG), biochemical and pathological. The guidelines apply to people with symptoms of ischemia and persistent ST segment elevation in the ECG (STEMI). In most of these patients stated a significant increase in levels of biochemical markers of myocardial necrosis and the formation of the typical heart attack pathological Q wave (according to the guidelines of the European Society of Cardiology - ESC).

  19. AMI – combination of data sources & adjustment Incidence by person Period prevalence General hospital morbidity study NHF database APPLIED APPLIED All patients treated in hospitals and by specialists in out-patient settings Statistical survey on mortality No information on GP’s patients Combination of data from 2 sources: General hospital morbidity study: number of discharged patients with AMI (including deaths in hospitals) Mortality data: number of deaths due to AMI outside the hospital (including persons not previously treated for the AMI in the hospital)

  20. Diabetes mellitus [E10-E14] • Data requirements: incidence by person, period prevalence, point prevalence • According to „Clinical recommendations for dealing with diabetes in 2010”, diagnostics, education and treatment of diabetes are conducted mailnly in primary care by GPs and in the specialised care by medical professionals. In case of complications, exacerbations and inability to achieve therapeutic effects in an out-patient care, there is a need for in-patient treatment • As a part of the specialist care – there are made the specialist diagnostics of all types diabetes and treatment of monogenic diabetes and diabetes co-occurring with other diseases. • Both - incidence by person and period prevalence - were estimated on the basis of the General out-patient morbidity study - the only one source of data on diabetes mellitus from primary out-patient care.

  21. Diabetes mellitus – a one to one relationship Incidence by person Period prevalence General outpatient morbidity study General outpatient morbidity study APPLIED APPLIED Data are provided by primary care physicians/ family doctors by whom DM is mainly diagnosed No data by sex and 5-year age groups available, only data for 0-18 and 19+ age groups NHF database REJECTED No information on GP’s patients Figure from this source 36,9% smaller than the number from General outpatient morbidity study Point prevalence NO DATA SOURCE

  22. Dementia (incl. Alzheimer disease) [F00-F03, G30] • Data requirements: period prevalence • Dementia case – recognized on the basis of clinical symptoms by a psychiatrist who orders proper pharmaceutical, psychological and psychoterapeutic treatment. Cases under consideration include: • Dementia in Alzheimer’s disease [F00, G30], • Vascular dementia (effect of brain infarction) [F01], • Dementia in other diseases elsewhere classified (Pick’s, Creutzfeld-Jakob’s, Huntington’s diseases, HIV) [F02] • Unspecified dementia [F03] • These diagnoses can be derived from psychiatric in-patient morbidity study which is based on individual statistical cards of patients. • Psychiatric out-patient morbidity study – wider range of codes [additionally: F04, F05, F06, F07, F09]; no identification of patients (only data on the aggregated level)

  23. Dementia – combination of data sources & adjustment NHF database (out-patients only) Period prevalence Psychiatric out-patient morbidity study APPLIED REJECTED Psychiatric in-patient morbidity study Psychiatric in-patient morbidity study • NHF – patients with a diagnosis corresponding to the required range of ICD-10 codes [F00-F03, G30] – counted only once (identified by PESEL number) • Psychiatric in-patient study: • the required ICD-10 codesavailable, • individual records derived from statistical cards • Connection of these data sources is improper • Reasons: • Out-patient morbidity study – • wider range of codes than required • possibility of double-counting – a patient using in-patient and out-patient psychiatric care in the same calendar year • no possibility for identification an individual patient

  24. Human immunodeficiency virus disease (HIV/AIDS) [B20-B24, Z21] • Data requirements: incidence by person, period prevalence, point prevalence • Cases of HIV/AIDS are defined in the system of reporting communicable diseases. The basis of diagnosis are clinical symptoms and/or immunological confirmation. • HIV infection – diagnosis based on laboratory criteria for HIV infection or AIDS diagnosis. There are detailed laboratory criteria for diagnosis, different for children under the age of 18 months and for the rest of people – adults, adolescents and children over 18 months. • AIDS – includes persons infected with HIV who have any of 28 clinical conditions listed in the European case definition for AIDS applied for epidemiological surveillance (European AIDS surveillance case definition) • HIV/AIDS register (notification and registration of HIV/AIDS) – was found as the best datasource

  25. HIV/AIDS – a one to one relationship Incidence by episode Period prevalence Register of HIV/AIDS Register of HIV/AIDS APPLIED APPLIED • Under-registration of seropositive cases: • unawareness of disease • confidentiality (sum of data in age groups ≠ total) Adjustment = all registered – deceased (from the beginning of registration to the end of 2005) Point prevalence General hospital morbidity study REJECTED Register of HIV/AIDS APPLIED • Difficulties in estimation of the number of seropositive cases: • no proper indication of new (first time) cases • overestimation • no all HIV/AIDS cases are hospitalized • underestimation Adjustment = all registered as of 30 December 2006 – deceased(from the beginning of registration to the end of 2006)

  26. Missing data INCOMPLETE DATA IN AGE AND GENDER GROUPS Incidence by episode Sum of numbers in age groups ≠ total number • HIV/AIDS Those listed on a register may retain their anonymity (age, gender) • Land transport accidents’ victims For some cases no information on age and gender NO RELAIBLE DATA SOURCE IDENTIFIED Incidence and prevalence • Pneumonia [J12-J18] • Accidental falls [W00-W19] • Accidental poisoning [X40-X49] • Intentional self harm (incl. suicidal attempt) [X60-X84] • Assault [X85-Y09] • Medical and surgical complications [Y40-Y66, Y69-Y84] Period prevalence • Rheumatoid arthritis [M05, M06] • Arthrosis [M15-M19]

  27. Future steps • Goal: regular morbidity data collection within the ESS • Task Force on morbidity statistics (TF MORB) was established • Fit existing methodological tools to that goal by • Analysis of results of 16 pilot studies in MS (stress on quality, reliability and comparability across MS) • 10 MS before 2009 (AT, CY, CZ, EE, HU, LT, LV, MT, SL, SI); for 6 MS (BE, DE, NL, RO, PL, FI) final report sent by autumn 2011 • If needed, revise the existing methodology: guidelines, shortlist of diseases • Deliverables discussed at a Technical Group MORB meeting • Finalisation of the documents by November 2012

  28. Thank you for the ATTENTION !!!

More Related